Search results for: myocardial infarction

Therapies Aimed at Immune Cell Progenitors May Be Key to Reducing Post Myocardial Infarction Risk

Lara C. Pullen, PhD | November 9, 2012

Researchers have identified hematopoietic stem and progenitor cells that are liberated from bone marrow niches by a myocardial infarction.

Heart Health: The Immunobiology of Cardiovascular Inflammation

Jason Liebowitz, MD, FACR | July 12, 2023

How do inflammatory pathways strain the cardiovascular system? Dr. Mark Gorelik provided insights into the inflammatory processes that influence heart recovery after myocardial infarction, Kawasaki disease, multi-system inflammatory syndrome in children and more.

Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease

Arthritis Care & Research | June 4, 2017

New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…

FDA Issues Stronger NSAIDs Warning

Michele B. Kaufman, PharmD, BCGP | July 29, 2015

The FDA revised its warning and labeling recommendations for antiinflammatory drugs because of a greater understanding of the increased risks they pose for stroke and myocardial infarction…

Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

Kimberly Retzlaff | April 2, 2014

Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered

Gout Research from ACR Convergence 2024 at a Glance

Lisa Stamp, MBChB, PhD | November 23, 2024

Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.

Gout & Its Comorbidities

Larry Beresford | January 22, 2024

At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.

The Risk of Cardiovascular Events in Patients with RA & More Explored in 3rd Plenary Session

Samantha C. Shapiro, MD | January 19, 2024

SAN DIEGO—In one presentation at Plenary Session 3, ACR Convergence 2023, Beth Wallace, MD, MSc, a staff physician at the VA Ann Arbor Healthcare System, Michigan, and an assistant professor at the University of Michigan, Ann Arbor, shared important data on the relationship between time-dependent cumulative glucocorticoid exposure and major adverse cardiovascular events (MACE) in a cohort of veterans with rheumatoid arthritis (RA).

Can SGLT2 Inhibitors Protect Our SLE Patients?

Samantha C. Shapiro, MD | December 4, 2023

SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.

The Great Debate 2023

Ruth Jessen Hickman, MD | December 4, 2023

SAN DIEGO—Panelists at ACR Convergence 2023 debate the merits of IL-6 inhibitors vs. glucocorticoids for the initial treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).